CBOA
ALXN

Commonwealth Bank of Australia’s Alexion Pharmaceuticals ALXN Stock Holding History

Commonwealth Bank of Australia’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-470
Closed -$59K – 1074
2019
Q2 		$59K Buy
470
+152
+48% +$19.6K ﹤0.01% 969
2019
Q1 		$41K Hold
318
– – ﹤0.01% 980
2018
Q4 		$28K Buy
318
+17
+6% +$2.01K ﹤0.01% 1000
2018
Q3 		$40K Buy
301
+100
+50% +$12.5K ﹤0.01% 1009
2018
Q2 		$23K Buy
201
+80
+66% +$9.35K ﹤0.01% 731
2018
Q1 		$12K Sell
121
-100
-45% -$12K ﹤0.01% 752
2017
Q4 		$24K Sell
221
-4
-2% -$487 ﹤0.01% 696
2017
Q3 		$30K Sell
225
-706
-76% -$95.9K ﹤0.01% 692
2017
Q2 		$112K Sell
931
-38
-4% -$4.42K ﹤0.01% 685
2017
Q1 		$118K Buy
969
+23
+2% +$2.96K ﹤0.01% 658
2016
Q4 		$116K Buy
946
+46
+5% +$5.63K ﹤0.01% 620
2016
Q3 		$111K Hold
900
– – ﹤0.01% 618
2016
Q2 		$105K Sell
900
-7
-0.8% -$993 ﹤0.01% 606
2016
Q1 		$126K Buy
907
+183
+25% +$26.9K ﹤0.01% 613
2015
Q4 		$137K Buy
724
+186
+35% +$32.5K ﹤0.01% 642
2015
Q3 		$84K Buy
538
+109
+25% +$19.9K ﹤0.01% 673
2015
Q2 		$77K Buy
429
+229
+115% +$39.5K ﹤0.01% 639
2015
Q1 		$35K Sell
200
-100
-33% -$18.1K ﹤0.01% 736
2014
Q4 		$56K Sell
300
-3,800
-93% -$704K ﹤0.01% 678
2014
Q3 		$680K Sell
4,100
-100
-2% -$16.4K 0.01% 549
2014
Q2 		$656K Sell
4,200
-12,578
-75% -$1.99M 0.01% 539
2014
Q1 		$2.55M Buy
16,778
+3,500
+26% +$557K 0.02% 598
2013
Q4 		$1.76M Buy
13,278
+1,578
+13% +$189K 0.01% 660
2013
Q3 		$1.36M Hold
11,700
– – 0.01% 672
2013
Q2 		$1.08M Buy
+11,700
New +$1.13M 0.01% 713

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Commonwealth Bank of Australia's ALXN Position: Q3 2019 in Review

Commonwealth Bank of Australia sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 470 shares — an estimated $59K sold.

Commonwealth Bank of Australia first reported a position in ALXN in Q2 2013 and held it in 25 quarters. The position peaked at $2.55M in Q1 2014. 647 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Commonwealth Bank of Australia reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Commonwealth Bank of Australia sold 470 Alexion Pharmaceuticals shares in Q3 2019, an estimated $59K.
  • Commonwealth Bank of Australia first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 25 quarters.
  • Commonwealth Bank of Australia's Alexion Pharmaceuticals position peaked at $2.55M in Q1 2014.
  • 647 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Commonwealth Bank of Australia's 13F filing for Q3 2019.